Importance of Vitamin D Therapy in Treatment of Neonatal SepsisPhase 3NCT05969327
Role of Vitamin D Therapy in Recovery From Early Neonatal Sepsis (Randomized Controlled Trial)
A Phase 3 study testing Vitamin D in people with Importance of Vitamin D Therapy in Treatment of Neonatal Sepsis, run by Ain Shams University at 1 site in Egypt.
Trial summary
Neonatal sepsis is still a major cause of morbidity and mortality despite major advances in neonatal intensive care units. Early-onset sepsis (EOS) is an infection of the blood acquired vertically from the mother and manifests shortly after birth. Read more about this study
- Who is it for?
- Ages 3 to 7 daysHealthy volunteers can take part
- Conditions the study is for
- Importance of Vitamin D Therapy in Treatment of Neonatal Sepsis
- What is being tested?
- Vitamin D
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteEgypt
- Study dates
- 14 Aug 2018to 27 Dec 2022
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 7 days
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- -Inclusion Criteria: full term newborns with clinical and laboratory findings of early onset of sepsis (EOS).
Who cannot join
- Preterm newborn, NPO neonates , infants with maternal risk factors , such as clinical and/or histological chorioamnionitis, neonates delivered at home ,neonates to mothers with premature rupture of membrane, and major congenital abnormalities which may be predisposing factors for development of EOS.
Trial locations and contacts
1 site in 1 country.
About this study
Neonatal sepsis is still a major cause of morbidity and mortality despite major advances in neonatal intensive care units. Early-onset sepsis (EOS) is an infection of the blood acquired vertically from the mother and manifests shortly after birth. The objective of this study is to assess the vitamin D status in neonates with Early onset sepsis (EOS) and evaluate the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), in these infants.
Read the detailed description
Subjects:
This is a randomized controlled trial (RCT) conducted on sixty (66) full term newborns with clinical and laboratory findings of early onset of sepsis (EOS) and admitted to the Neonatal Intensive Care Unit of El-Demerdash hospital of Ain Shams university and El Ahrar teaching hospital in Zagazig.
- Inclusion Criteria: full term newborns with clinical and laboratory findings of early onset of sepsis (EOS).
- Exclusion Criteria: Preterm newborn, NPO neonates , infants with maternal risk factors , such as clinical and/or histological chorioamnionitis, neonates delivered at home ,neonates to mothers with premature rupture of membrane, and major congenital abnormalities which may be predisposing factors for development of EOS.
NB: we excluded the dead cases (6 cases) in the final laboratory and clinical relation with serum Vitamin D levels after recovery because sepsis caused death to these neonates and recovery didn't occur .
Methods:
An informed consent was taken from the legal guardian of the newborns participating in the study.
Detailed history taking from all mothers of neonates in the study laying stress on vitamin D supplementation during pregnancy, sun exposure in mothers during pregnancy, place and mode of delivery. Dietetic history in all included mothers (National Nutrition institute, 2006). Clinical evaluation of all newborns for signs of neonatal sepsis.
All subjects in the study were subjected to the following:
- Clinical Examination: General examination including vital data; temperature, pulse, respiratory rate, anthropometric measurements including weight and length (Neonatal Anthropometry): In all neonates weight (in Kg) was recorded on an electronic weighing scale at birth. Length (in cm) was recorded by measuring tape. SDS of weight and length was calculated and plotted against appropriate growth curves (Tanner et al., 1968).
- Laboratory Investigations: Under aseptic conditions venous blood samples was collected into sterile blood collection tubes and the following investigations was performed:
- A neonatal sepsis screen including: total leukocyte count, absolute neutrophil count, platelet count immature to total neutrophil count and C-reactive protein (CRP).
- Blood samples for complete blood count (CBC) and blood culture. All patients were initially assessed according to Newborn Scale of Sepsis.
- A total clinical score less than 10 indicated that the newborn did not have sepsis-a negative predictive value of 97%.
- Any neonate with a total clinical score greater than 10 was considered ''sick,'' possibly with sepsis. A clinical score greater than 10 is also an indicator of the need for further diagnostic evaluation (Gardner, 2008).
- Serum 25 (OH) vitamin D levels: was measured by Human Vitamin D ELISA Kit (Qualpro diagnostics, INDIA) in all newborns on the first day of sepsis, 25(OH) vitamin D levels were classified according to the guidelines of the Endocrine Society to the following reference values:
- Sufficient >20 ng/ml (>50 nmol/l)
- Insufficient 12-20 ng/ml (30-50 nmol/l)
- Deficient <12 ng/ml (<30 nmol/l) (Munns et al., 2016).
Study design : Subjects were classified into three groups :
GROUP A (conventional dose Vitamin D) those neonates who received a daily dose of oral Vitamin D of 400 IU through Ryle or mouth from onset of diagnosis till recovery from sepsis.
GROUP B (higher dose Vitamin D) those neonates who receiveda daily dose of oral vitamin D of 800 IU through ryle or mouth from onset of diagnosis till recovery from sepsis.
GROUP C (Placebo group) those neonates with early onset sepsis who did not receive any vitamin D supplementation.
Patients were matched regarding sepsis score. All 3 groups were treated using strategy of sepsis treatment.
- Reevaluation of serum Vitamin D levels for all patients on recovery(recovery was assessed by Newborn Scale of Sepsis to be less than 10).
- Serum Ca and P were measured initially for all patients upon diagnosis of EOS, and on discharge upon recovery Normal range of Ca 8.8-11.3mg/dl Normal range P 4.5-6.2 mg/dl
- Urinary Ca will be evaluated after two weeks of onset of vitamin D therapy (for patients who experience elevation of serum Ca above normal value).
Type of Study: Randomized controlled study. Study Setting: This study was conducted on sixty (66) full term newborns with clinical and laboratory findings of early onset of sepsis (EOS) and were admitted to the Neonatal Intensive Care Unit of El-Demerdash hospital of Ain Shams university and El Ahrar teaching hospital in Zagazig.
- Study Period: The study took place from January 2018 to January 2021.
- Study Population: Full term newborns with early onset sepsis.
- Sampling Method: random.
- Sample Size:
Using PASS program, setting alpha error at 5% and power at 80%. After reviewing literature, no previous similar study has been done before. So assuming that NICU duration for placebo, 400IU vitamin D and 800 IU vitamin D respectively is 7±2.5, 5.5±2.5, 4±2.5 based on this, the needed sample is 20 cases per group (total 60).
- Ethical Considerations:
- The consent was conducted to the legal guardian or the parents of our patients by the investigator.
- Premature termination of oral vitamin D was mandatory for patients with abdominal distension or feeding intolerance.
- All data was treated confidentially and was not be allowed except to the principle investigator.
- Being tested
- Vitamin D
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin DDrug
oral supplementation of two different doses
| Study group | Role | What they receive |
|---|---|---|
| with out vitamin D | No intervention | neonates without supplementation |
| Vitamin D 400 IU | Experimental | neonates with 400 IU supplementation Receives: Drug: Vitamin D |
| Vitamin D 800 IU | Experimental | neonates with 800 IU supplementation Receives: Drug: Vitamin D |
What is being measured
The primary outcome is the main question the study is designed to answer.
Role of Vitamin D therapy in recovery from Early Neonatal Sepsis (randomized controlled trial)
supplementation of Vitamin D
Measured: nearly 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2023
- Study start14 Aug 2018
- Primary completion6 Sep 2022
- Study completion27 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Importance of Vitamin D Therapy in Treatment of Neonatal SepsisStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05969327
- Sponsor's protocol ID
- MD 438/ 2017
- Status last verified
- Dec 2017
- First submitted
- 23 Jul 2023
- Last updated
- 24 Aug 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Vitamin D Therapy in Recovery From Early Neonatal Sepsis (Randomized Controlled Trial)
- ClinicalTrials.gov ID
- NCT05969327
- Acronym / sponsor ID
- MD 438/ 2017
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 14 Aug 2018 (actual)
- Primary completion
- 6 Sep 2022 (actual)
- Study completion
- 27 Dec 2022 (actual)
- First posted
- 1 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neonatal sepsis is still a major cause of morbidity and mortality despite major advances in neonatal intensive care units. Early-onset sepsis (EOS) is an infection of the blood acquired vertically from the mother and manifests shortly after birth. The objective of this study is to assess the vitamin D status in neonates with Early onset sepsis (EOS) and evaluate the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), in these infants.
Detailed description
Subjects:
This is a randomized controlled trial (RCT) conducted on sixty (66) full term newborns with clinical and laboratory findings of early onset of sepsis (EOS) and admitted to the Neonatal Intensive Care Unit of El-Demerdash hospital of Ain Shams university and El Ahrar teaching hospital in Zagazig.
- Inclusion Criteria: full term newborns with clinical and laboratory findings of early onset of sepsis (EOS).
- Exclusion Criteria: Preterm newborn, NPO neonates , infants with maternal risk factors , such as clinical and/or histological chorioamnionitis, neonates delivered at home ,neonates to mothers with premature rupture of membrane, and major congenital abnormalities which may be predisposing factors for development of EOS.
NB: we excluded the dead cases (6 cases) in the final laboratory and clinical relation with serum Vitamin D levels after recovery because sepsis caused death to these neonates and recovery didn't occur .
Methods:
An informed consent was taken from the legal guardian of the newborns participating in the study.
Detailed history taking from all mothers of neonates in the study laying stress on vitamin D supplementation during pregnancy, sun exposure in mothers during pregnancy, place and mode of delivery. Dietetic history in all included mothers (National Nutrition institute, 2006). Clinical evaluation of all newborns for signs of neonatal sepsis.
All subjects in the study were subjected to the following:
- Clinical Examination: General examination including vital data; temperature, pulse, respiratory rate, anthropometric measurements including weight and length (Neonatal Anthropometry): In all neonates weight (in Kg) was recorded on an electronic weighing scale at birth. Length (in cm) was recorded by measuring tape. SDS of weight and length was calculated and plotted against appropriate growth curves (Tanner et al., 1968).
- Laboratory Investigations: Under aseptic conditions venous blood samples was collected into sterile blood collection tubes and the following investigations was performed:
- A neonatal sepsis screen including: total leukocyte count, absolute neutrophil count, platelet count immature to total neutrophil count and C-reactive protein (CRP).
- Blood samples for complete blood count (CBC) and blood culture. All patients were initially assessed according to Newborn Scale of Sepsis.
- A total clinical score less than 10 indicated that the newborn did not have sepsis-a negative predictive value of 97%.
- Any neonate with a total clinical score greater than 10 was considered ''sick,'' possibly with sepsis. A clinical score greater than 10 is also an indicator of the need for further diagnostic evaluation (Gardner, 2008).
- Serum 25 (OH) vitamin D levels: was measured by Human Vitamin D ELISA Kit (Qualpro diagnostics, INDIA) in all newborns on the first day of sepsis, 25(OH) vitamin D levels were classified according to the guidelines of the Endocrine Society to the following reference values:
- Sufficient >20 ng/ml (>50 nmol/l)
- Insufficient 12-20 ng/ml (30-50 nmol/l)
- Deficient <12 ng/ml (<30 nmol/l) (Munns et al., 2016).
Study design : Subjects were classified into three groups :
GROUP A (conventional dose Vitamin D) those neonates who received a daily dose of oral Vitamin D of 400 IU through Ryle or mouth from onset of diagnosis till recovery from sepsis.
GROUP B (higher dose Vitamin D) those neonates who receiveda daily dose of oral vitamin D of 800 IU through ryle or mouth from onset of diagnosis till recovery from sepsis.
GROUP C (Placebo group) those neonates with early onset sepsis who did not receive any vitamin D supplementation.
Patients were matched regarding sepsis score. All 3 groups were treated using strategy of sepsis treatment.
- Reevaluation of serum Vitamin D levels for all patients on recovery(recovery was assessed by Newborn Scale of Sepsis to be less than 10).
- Serum Ca and P were measured initially for all patients upon diagnosis of EOS, and on discharge upon recovery Normal range of Ca 8.8-11.3mg/dl Normal range P 4.5-6.2 mg/dl
- Urinary Ca will be evaluated after two weeks of onset of vitamin D therapy (for patients who experience elevation of serum Ca above normal value).
Type of Study: Randomized controlled study. Study Setting: This study was conducted on sixty (66) full term newborns with clinical and laboratory findings of early onset of sepsis (EOS) and were admitted to the Neonatal Intensive Care Unit of El-Demerdash hospital of Ain Shams university and El Ahrar teaching hospital in Zagazig.
- Study Period: The study took place from January 2018 to January 2021.
- Study Population: Full term newborns with early onset sepsis.
- Sampling Method: random.
- Sample Size:
Using PASS program, setting alpha error at 5% and power at 80%. After reviewing literature, no previous similar study has been done before. So assuming that NICU duration for placebo, 400IU vitamin D and 800 IU vitamin D respectively is 7±2.5, 5.5±2.5, 4±2.5 based on this, the needed sample is 20 cases per group (total 60).
- Ethical Considerations:
- The consent was conducted to the legal guardian or the parents of our patients by the investigator.
- Premature termination of oral vitamin D was mandatory for patients with abdominal distension or feeding intolerance.
- All data was treated confidentially and was not be allowed except to the principle investigator.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| with out vitamin D | No intervention | –neonates without supplementation |
| Vitamin D 400 IU | Experimental | Drug: Vitamin Dneonates with 400 IU supplementation |
| Vitamin D 800 IU | Experimental | Drug: Vitamin Dneonates with 800 IU supplementation |
Who may qualify
- Ages
- 3 to 7 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- -Inclusion Criteria: full term newborns with clinical and laboratory findings of early onset of sepsis (EOS).
Key exclusion criteria (1 listed)
- Preterm newborn, NPO neonates , infants with maternal risk factors , such as clinical and/or histological chorioamnionitis, neonates delivered at home ,neonates to mothers with premature rupture of membrane, and major congenital abnormalities which may be predisposing factors for development of EOS.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin Doral supplementation of two different doses | Drug | Vitamin D 400 IU, Vitamin D 800 IU |
Primary outcome
Role of Vitamin D therapy in recovery from Early Neonatal Sepsis (randomized controlled trial)
Time frame: nearly 4 years
supplementation of Vitamin D
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2023.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vitamin D in people with Importance of Vitamin D Therapy in Treatment of Neonatal Sepsis, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Role of Vitamin D therapy in recovery from Early Neonatal Sepsis (randomized controlled trial) (time frame: nearly 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2023.